Cancer research groups push emergency funding to restart clinical trials in infrastructure package

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A group of more than 50 cancer research-focused organizations are urging Congress to include $10 billion in emergency funding to restart cancer research and clinical trials at the National Institutes of Health stalled by the coronavirus pandemic.

In a letter sent to lawmakers, members of the One Voice Against Cancer coalition say without the additional resources in the forthcoming American Jobs Plan, promising research will languish and potentially be lost entirely.

“The pandemic’s impact on cancer research has been severe. Early shutdowns forced research to come to an abrupt halt, and restarting trials has required implementing new protocols, procuring personal protective equipment and sometimes restarting work altogether that otherwise could not be resumed,” Lisa Lacasse, president of the American Cancer Society Cancer Action Network, said in a statement. “The cost of these disruptions has been significant and threatens to jeopardize progress in the effort to reduce our country’s cancer burden for years to come.”

“Clinical trials are often the best and sometimes only course of treatment for patients in need of care. On behalf of all cancer patients, survivors and their families, we urge Congress to include this additional NIH funding in the American Jobs Plan and ensure medical research can keep moving forward without delay.”

Table of Contents

YOU MAY BE INTERESTED IN

On Feb. 19, GRAIL Inc. announced that its pivotal NHS-Galleri trial failed to meet its primary endpoint of reduction in advanced stage cancers. The media and the market reacted as one would expect: GRAIL’s stock price halved the day after the announcement and at least three law firms said that they are conducting investigations in preparation for filing investor suits.
If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login